Shukra Pharmaceuticals Intrinsic Value
Shukra Pharmaceuticals (SHUKRAPHAR) median intrinsic value is ₹24.70 from 4 valuation models (range ₹17–₹41), vs current price ₹55.93 — -55.8% downside (Trading Above Calculated Value), margin of safety -100.0%. For current market price and key ratios, visit Shukra Pharmaceuticals share price screener.
SHUKRAPHAR Valuation Methods Summary — DCF, Graham Number & P/E
Shukra Pharmaceuticals intrinsic value across 4 models vs current price ₹55.93 — upside/downside and value range per method. Check Shukra Pharmaceuticals marketcap in USD to track the company's total market size over time.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| Book Value Method | asset | ₹40.91 | ₹36.82 - ₹45.00 | -26.9% | Book Value/Share: ₹20.45, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹16.78 | ₹15.10 - ₹18.46 | -70.0% | Revenue/Share: ₹6.36, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹22.37 | ₹20.13 - ₹24.61 | -60.0% | EBITDA: ₹8.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹24.70 | ₹19.76 - ₹29.64 | -55.8% | CF Growth: 15.0%, Discount: 15% |
SHUKRAPHAR Intrinsic Value vs Market Price — All Valuation Models
Shukra Pharmaceuticals fair value range ₹17–₹41 vs current market price ₹55.93 across 4 valuation models. See Shukra Pharmaceuticals P/B valuation to compare market price against book value per share.
SHUKRAPHAR Intrinsic Value Analysis — Undervalued or Overvalued?
Shukra Pharmaceuticals median intrinsic value ₹24.70, current price ₹55.93 — Trading Above Calculated Value by 55.8%, margin of safety -100.0%.
What is the intrinsic value of SHUKRAPHAR?
Based on our comprehensive analysis using 4 different valuation methods, the estimated intrinsic value of Shukra Pharmaceuticals (SHUKRAPHAR) is ₹24.70 (median value). With the current market price of ₹55.93, this represents a -55.8% variance from our estimated fair value.
The valuation range spans from ₹16.78 to ₹40.91, indicating ₹16.78 - ₹40.91.
Is SHUKRAPHAR undervalued or overvalued?
Based on our multi-method analysis, Shukra Pharmaceuticals (SHUKRAPHAR) appears to be trading above calculated value by approximately 55.8%.
SHUKRAPHAR Financial Health — Key Ratios vs Industry Benchmarks
Shukra Pharmaceuticals financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 16.80 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | -8.9% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 11.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.24x | Industry Standard: 1.0x+ | Below 0.5x | Measures asset utilization efficiency |
SHUKRAPHAR Cash Flow Quality — Operating & Free Cash Flow
Shukra Pharmaceuticals operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹8 Cr | ₹8 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹-5 Cr | ₹-6 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹3 Cr | ₹1 Cr | Positive Free Cash Flow | 7/10 |
| March 2022 | ₹8 Cr | ₹7 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹1 Cr | ₹0 Cr | Positive Operating Cash Flow | 6/10 |